Reading ABT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ABT free→
ABT
Abbott LaboratoriesNYSEHealth CareMedical DevicesSnapshot 2026-06-12
Intact
$88.18-1.64%
Close 2026-06-12 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality is neutral, and the sector backdrop is a headwind, which may pose challenges. Peer multiples imply a price about 24% above where it trades (it looks cheap on this basis); the read is fair. Key factors to watch include any potential cuts to guidance and the performance of sector bellwethers, as these could significantly influence ABT's outlook.
as of 2026-06-12
Quick facts
- Exchange
- NYSE
- Sector
- Health Care
- Industry
- Medical Devices
- Market cap
- $156.15B
- Employees
- 115,000
- IPO date
- 1929-03-09
- Next earnings
- 2026-07-16
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 7 valuation methods, at three horizons. Current price $88.18. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryinexpensive
$122.71consensus
Range $107.18 – $124.60
vs price: -28% below
Method agreement — · 7 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearinexpensive
$163.57consensus
Range $123.70 – $168.10
vs price: -46% below
Method agreement — · 6 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Cheap vs peershigh confidence
At $88 ABT trades at 17× p/e, below its 23× p/e peer median. Our $123 fair value sits above the price; high confidence. Analysts: $92–$158. Not investment advice.
Multiple (P/E)
16.9x
peer 23.3x · own history 23.6x
Premium
0.7x peer
0.7x its own history
Growth the price needs
-28%
our forecast 12%
Our fair value
$122.71
range $107.18 – $124.60
Analyst range(a guide on our number, not a target)Our number is in the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
inexpensivefair12-month view
What's priced inJustified
The price implies about 28% below a flat-multiple fair value, below our forecast of about 12%. This describes what's priced in, not a forecast of the move.
Low fragilityrisk posture, not a price call
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Historical context
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
83rd pctl · Health Care
Earnings quality
neutralOver the trailing year it converted 1.51x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
50th pctl · Health Care
Macro sensitivity
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
Management & capital allocation
volatile10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Strongly bearish22 analysts, 75% Buyfor period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $1.28 → $1.28 (-0.0% / 30d). 0 raised, 2 cut, 22 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d. 75% of analysts rate Buy.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: strong
- Capital allocation
- strong
- Earnings discipline
- strong
- Margin discipline
- strong
- Balance sheet
- neutral
- Guidance credibility
- strong
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$93.
How much price usually moves either way.
On a bad day, this stock has moved -$218.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,898.
Deepest peak-to-trough drop in the last year.
moderateas of 2026-06-12
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- score change · guidance_credibility_scoremoderate change
Guidance credibility rose by 25.0 points (from 75.0 to 100.0).
- score change · management_scoresmall change
Management rose by 9.9 points (from 78.3 to 88.2).
- label change · valuation_labelsmall change
Valuation label changed from 'fair' to 'inexpensive'.
Guidance credibility rose. Management also rose. Both changes indicate stronger confidence in the company.
as of 2026-06-12
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- DownsideHigh confidenceMonthsactive 14d
Watch for Q2 2026 adjusted diluted EPS below $1.25
Why it matters: Lower EPS shows problems in growing after the Exact Sciences purchase.
What confirms / what disproves
Confirms:Q2 2026 adjusted diluted EPS was below $1.25.
Disproves:Q2 2026 adjusted diluted EPS was above $1.31.
Earnings call
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ABT yet.
This sector is also watching
- Watch for Health Care revenue growth dropping below 8% YoY
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like SYK, MDT, and BSX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting ABT and other Healthcare names. Worth watching these names for early signals.
- If ABT raises forward guidance on the next earnings call (currently NEW as of 2026-04-16), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for ABT and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If ABT cuts guidance on the next call (currently NEW as of 2026-04-16), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like SYK, MDT, and BSX start missing or guiding lower, the Healthcare tailwind helping ABT and other Healthcare names could fade. Watch these names for early warning.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-161mo agoItem 2.02
Results of Operations and Financial Condition On April 16, 2026, Abbott Laboratories announced its results of operations for the first quarter 2026. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictabl…
Earnings preannouncementneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+13 vs last weeklatest as of 2026-06-13
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.